SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing heightened volatility as the community debates the impact of MSCI index exclusion risks alongside ongoing share dilution, while traders remain sharply divided over whether the stock is a prime short candidate or a leveraged accumulation play for a Bitcoin recovery.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber shares plummeted following the announcement of a $250 million private placement of convertible senior notes due in 2032, sparking intense community debate over potential equity dilution versus the capital needed to fund data center expansion. While some investors view the sell-off as an attractive buying opportunity for a data center play, others are expressing significant skepticism, labeling the stock a manipulated scam and warning of further volatility.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital Inc. is trending as investors react to a state-led validation of its operations as a tier-one data center operator, which many community members believe eases regulatory uncertainty. Despite the positive news and support from institutional filings, discussion remains polarized between those anticipating a major breakout and those expressing frustration over recent price volatility.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently facing heavy downward pressure amid broader market volatility, with the community sharply divided between those viewing the price decline as a prime accumulation opportunity and critics labeling the project a failing investment. Investors are actively debating the token's long-term utility and the lack of recent leadership communication, even as bulls continue to aggressively average down in anticipation of future recovery.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is surging after reporting positive Phase 3 LUCIDITY trial results for its drug candidate avexitide, which successfully met its primary endpoint in treating post-bariatric hypoglycemia. The stock's sharp rise is further fueled by a major 350 million dollar common stock offering that investors are absorbing as a move to secure the company's financial runway for commercialization efforts.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is capturing significant attention as institutional interest grows through tokenized real-world assets and increased stablecoin settlement volume. While market participants remain focused on potential regulatory catalysts and macro-economic shifts, the community is actively debating whether current price levels offer a strategic accumulation opportunity for the next market cycle.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is facing intense downward price pressure and community skepticism, with investors debating whether the current sell-off by whales represents a capitulation event or a fundamental failure of the project's utility. While some holders view the volatility as a generational buying opportunity tied to long-term partnerships in the Middle East and payment rail integration, others are increasingly vocal about their lack of trust in management and the token's inability to sustain gains.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The QQQ is experiencing heightened volatility driven by geopolitical tensions in the Middle East, rising global bond yields, and investor anxiety over AI sector valuations. The community is actively debating whether current price action represents a temporary dip-buying opportunity or the beginning of a larger market correction as traders monitor key gamma levels and upcoming macro catalysts.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is trending following a major Phase 2 clinical readout for its internal menopause candidate, ABCL635, which significantly outperformed current benchmarks and validated the company's proprietary drug discovery platform. The community is actively debating the stock's long-term valuation potential while closely monitoring heavy insider buying and a significant short interest, leading to intense speculation regarding a potential short squeeze.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is currently facing intense volatility and legal scrutiny as a power struggle over board leadership and CEO succession intensifies between founder Vishal Garg and the current board. The community is actively debating the impact of the leadership dispute on shareholder value while analyzing the stock's potential as a speculative turnaround play driven by its AI-integrated Tinman platform and recent fintech partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million.
BeyondSpring (NASDAQ:BYSI) shares movedread more...

Liminatus Pharma Buys More Time, September 3 Deadline is Now the Catalyst

Liminatus Pharma (NASDAQ:LIMN) has cleared one immediate Nasdaq hurdle, but the clock is still running. The company announced that its common stock transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective August 4, 2026, while the Nasdaq Hearings Panel granted Liminatus additional time to regain compliance with the exchange’s minimum bid price requirement. The new deadline is September 3, 2026, giving the company several more weeks to demonstrate compliance while allowing LIMN to continue trading on Nasdaq under its existing ticker.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million.
LENSAR (NASDAQ:LNSR) shares increased byread more...

Gainers

Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's regular session. The company's market cap stands at $7.6 million.
Agape ATP (NASDAQ:ATPC) shares moved upwards byread more...

11 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million.
Liminatus Pharma (NASDAQ:LIMN)read more...

Liminatus Pharma (LIMN) Stock Is Trending Overnight  Here's Why it Spiked Over 30% in After-Hours Session (UPDATED)

Liminatus Pharma shares surged 30.49% in after-hours trading following an amended InnocsAI merger deal that speeds up closing.read more...

The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Liminatus Pharma Is Trending Overnight  Here's Why LIMN Stock Surged Over 79% In After-Hours Session

Liminatus Pharma Inc. shares soared in after-hours trading after the company announced a merger agreement with InnocsAI LLC.read more...

Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance 

Equity

The company had previously faced a notice for delayed filings but has since rectified the issue.

Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in Cerritos, CA.

Liminatus Pharma Inc. - Ordinary Shares - Class A

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

LIMNLiminatus Pharma Inc.

Fundamentals

Connect Stocktwits to ChatGPT

Latest LIMN News